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Abstract
Coronavirus disease 2019 (COVID-19) has affected over 200 million patients worldwide. COVID-19 is transmitted through
respiratory droplets from patient to patient or by touching a surface that has been contaminated by an infected patient.
Many COVID-19 patients have other comorbidities, such as end-stage renal disease. Currently, management of COVID-19
in patients with end-stage renal disease is unclear. Some studies have shown improvement in this population with the
use of tocilizumab, a humanized interleukin-6 monoclonal antibody, in addition to the standard therapy as per guidelines
published by the National Institutes of Health. In this case report, we present a patient case where the use of remdesivir,
tocilizumab, and pulse-dose methylprednisolone significantly improved symptoms and inflammatory biomarkers associated
with COVID-19 in a patient with end-stage renal disease.
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Critical care/emergency medicine, nephrology, infectious diseases, COVID-19, steroids, remdesivir, tocilizumab, end-stage
renal disease
Date received: 31 August 2021; accepted: 7 December 2021

Introduction
Coronavirus disease 2019 (COVID-19) is caused by a Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)
transmitted through respiratory droplets from patient to
patient. SARS-COV-2 is made up of four structural proteins,
including spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins.1 The S protein is responsible for viral
binding to the host cell receptor and entry into the host cell
membrane. Once in the membrane, the viral contents are
released and begin to replicate through RNA polymerase
activity creating new strands of positive RNAs. The N protein binds to the new RNA, forming nucleocapsids that are
enclosed in the endoplasmic reticulum and eventually transported to the extracellular space via exocytosis.2 This progression ultimately leads to an uncontrolled inflammatory
response due to a rapid increase in proinflammatory
cytokines, mainly interleukin (IL)-6, causing a cytokine
storm and acute respiratory distress syndrome (ARDS).
Several other inflammatory markers have been detected with
COVID-19, which include elevated levels of serum ferritin,
C-reactive protein (CRP), procalcitonin, alanine transaminase (ALT), and aspartate aminotransferase (AST).1

With the rising death tolls due to COVID-19, clinicians
have used a wide variety of combinations of medications to
curtail the mortality rate. Despite ongoing clinical trials and
retrospective publications, there is no current consensus on
pharmacotherapy. Currently, clinicians have used remdesivir, corticosteroids, and tocilizumab for treatment.
Remdesivir, Food and Drug Administration (FDA)-approved
in October 2020, is a broad-spectrum antiviral that inhibits
the RNA-dependent RNA polymerase.2 Glucocorticoids
exhibit an anti-inflammatory effect that can decrease IL-6,
IL-8, and TNF receptor 1, which are all inflammatory markers that were found to be elevated in COVID-19 patients.3
Finally, tocilizumab, a humanized anti IL-6 monoclonal antibody, selectively and competitively binds to soluble expressing IL-6 preventing a cytokine storm (see Figure 1).4
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Figure 1. Mechanism of action of tocilizumab, remdesivir, and methylprednisolone in COVID-19. Tocilizumab binds to the IL-6 binding
site of human IL-6R and competitively inhibits IL-6 signaling, thereby interfering with the cytokine storm.5 Remdesivir inhibits RNAdependent RNA polymerase, preventing new RNA strands.6 Methylprednisolone binds to glucocorticoid receptors after diffusing across
the cell membrane, where it causes a conformational change in the receptor and restricts macrophage activation. Methylprednisolone
also inhibits TNF-alpha receptor, which downregulates activation of cytokines, preventing a cytokine storm.7

Case presentation
Our patient was a 75-year-old Caucasian male with a prominent past medical history of ESRD, hypertension, diabetes,
and benign prostatic hyperplasia who provided written
informed consent. The patient had a recent surgery for spinal
stenosis and was recuperating at a nursing home where he
contracted COVID-19. Patient noted that he has been compliant with his dialysis schedule. When he was brought to the
emergency department due to worsening shortness of breath,
he was found to be hypoxic with an 87% SpO2 on room air.
The initial chest X-ray revealed bilateral infiltrates consistent with multifocal bronchiolitis pneumonia (see Figure 2).
His SARS-COV-2 antigen and PCR test were both positive
upon admission, and his CRP was elevated. On day 1, the
patient was admitted to the general hospital ward on 4 L of
oxygen with an SpO2 of 91%. However, his respiratory status worsened on day 2 and oxygen requirement escalated to
15 L with saturation in the high 90’s. His arterial blood gas
showed a pH of 7.43, PaCO2 of 42.0 mmHg, PaO2 of
78.0 mmHg, and SO2 of 96.2 while on 15 L high flow nasal
cannula (HFNC). He was then transferred to the intensive
care unit (ICU) for closer monitoring.
Initially, the patient was treated with one dose of dexamethasone 10 mg IV push and bamlanivamab and etesevimab. However, upon ICU transfer, the patient was started
on methylprednisolone 1 g for 3 days per our ICU COVID19 protocol. Originally, remdesivir and tocilizumab were

Figure 2. The chest X-ray showed multifocal bilateral patchy
interstitial and alveolar infiltrates. No pneumothorax was present.
Findings were consistent with multifocal bronchiolitis pneumonia
consistent with the history of COVID-19 pneumonia.

held due to the patient’s history of ESRD and concern for
toxicity. After deliberation with other specialties, the patient
was started on remdesivir 200 mg for 1 day, followed by
remdesivir 100 mg for 4 days, as well as tocilizumab 8 mg/
kg for 1 dose on day 2. After the pulse dose of methylprednisolone was completed, the patient was started on methylprednisolone 40 mg twice a day. Within a few days of
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Table 1. Progression of biological parameters from day 1 of hospital admission to discharge.
Measure

Day 1

Day 2a

Day 3

Day 4

Day 5

Day 6b

Day 7

White cell count (109/L)
Neutrophil count (%)
Lymphocyte count (%)
Hemoglobin (g/dL)
Hematocrit (%)
Platelet count (109/L)
CRP (mg/L)
Ferritin (µg/L)
ALT (U/L)
AST (U/L)
FIO2% (L/min)

5.14
77.7
10.7
8.4
26.3
179
136
NA
NA
NA
4 L NC

8.39
89.4
5.2
9.7
30.1
238
NA
NA
9
19
15 L HFNC

8.03
89.4
6.5
9.8
29.5
277
120.6
5340
9
18
100 % @ 50 L

8.46
86.7
5.1
9.1
27.4
295
76.3
5047
10
18
40% @ 40 L

10.39
82.7
4.9
9.5
28.4
346
53.8
4480
15
18
2 L NC

14.27
81.1
4.9
9.8
28.9
314
38.6
3882
24
23
Room air

18.44
80.8
5.6
9.9
29.6
349
27.6
3803
26
20
Room air

CRP: C-reactive protein; NA: not available; ALT: alanine transaminase; UL: units per liter; AST: aspartate aminotransferase; FIO: fraction of inspired
oxygen; NC: nasal cannula; HFNC: high flow nasal cannula.
The patient received hemodialysis on days 3, 4, 5, and 7 of his hospital stay.
a
Remdesivir day 1 and tocilizumab administration.
b
Completion of remdesivir treatment.

treatment, the patient had substantial improvement in oxygen requirement as well as inflammatory biomarkers. He
was discharged on day 7 after being hemodynamically stable for more than 48 h (see Table 1). His liver function tests
were within normal limits (shown in Table 1) throughout the
duration of therapy and hospital stay. Patient has end-stage
renal disease (ESRD), therefore, creatinine clearance was
not trended. No liver necrosis or acute kidney injury was
seen during or after completion of triple combination therapy in our patient. Due to the available resources at our
community hospital, we did not have access to measure
interleukin (IL)-6, IL-8, IL-2, and transferrin receptor (TF)
receptor. We did analyze CRP and serum ferritin. Patient
was observed for any adverse events related to remdesivir
and tocilizumab, including hypersensitivity reactions, bradycardia, and increased hepatic effects.

Discussion
Shortly after first being reported in Wuhan, China in
December 2019, COVID-19 became a global, ongoing pandemic that has been linked with high mortality. According to
the World Health Organization, as of early August 2021, there
have been over 200 million cases of COVID-19 confirmed
worldwide, including 4.2 million deaths.4 Signs and symptoms of COVID-19 include shortness of breath, cough, fever,
nausea, vomiting, or loss of taste and smell. These can appear
anywhere from 2 to 14 days post exposure, whereas some
patients have no symptoms but can still spread the disease. It
has been noted that patients have a higher risk of contracting
COVID-19 with risk factors such as old age, immunosuppression, diabetes, ESRD, or cardiac and pulmonary disease.2
At the time of this patient case in July 2021, there were no
case reports which showed the use of this triple therapy regimen in a patient with ESRD that resulted in successful recovery. Unfortunately, the treatment for COVID-19 patients,

specifically with ESRD, is poorly understood due to lack of
data or evidence at this time.
Although there is literature to support the safe use of remdesivir and tocilizumab in individuals with normal liver and
kidney function, there have been concerns in using it in
patients with ESRD. Remdesivir is a prodrug mainly metabolized by hepatic enzymes to remdesivir triphosphate, which
is a nucleotide analog that prevents replication of SARSCOV-2.4 The plasma half-life of the parent drug remdesivir
is 1–2 h. However, the half-life of the active metabolite remdesivir triphosphate is about 20–25 h.4 Remdesivir also contains the inactive ingredient, sulfobutylether-β-cyclodextrin
(SBE-β-CD), which is a large, cyclic oligosaccharide mainly
excreted through glomerular filtration that has an elimination half-life of less than 2 h. SBE-β-CD has been shown to
accumulate in patients with a creatinine clearance less than
50 mL/min.6 Hence, there is concern for liver necrosis and
renal tubule obstruction with using remdesivir in ESRD
patients.5 Currently, manufacturer’s labeling does not recommend its use in this population.7
However, there was an observational prospective study
published in March 2021 with 48 dialysis-dependent patients
diagnosed with COVID-19 who received remdesivir. During
the treatment period, 100 mg of remdesivir was given 4 h
before hemodialysis sessions. In this study, the researchers
did not see a significant alteration in liver function tests and
CRP levels improved. This study concluded no liver necrosis
or acute kidney injury and if remdesivir is initiated within
48 h of hospitalization in ESRD patients, it reduces recovery
time.5 There have also been several case reports on the use of
remdesivir in a patient with ESRD. One case report initially
used dexamethasone, and 10 days later administered remdesivir due to worsening symptoms. There were no signs of drugrelated toxicity and oxygen parameters improved on day 5 of
treatment with remdesivir.8 Another single-center trial of 157
COVID-19 patients with ESRD studied the use of remdesivir
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and dexamethasone. The authors reported that no clinically
significant ALT elevations were observed, and no patients
needed early discontinuation of therapy due to adverse
effects.9 Although there are retrospective studies to demonstrate the safety of the remdesivir in ESRD patients, there are
no reports of using the triple therapy as noted in our study.
In regard to tocilizumab, it is known to have biphasic
elimination from the circulation following intravenous
administration. Its pharmacokinetics show a volume distribution of 6.4 L at steady state. The concentration-apparent
half-life is 11 days for 4 mg/kg and 13 days for 8 mg/kg.10
No large, randomized controlled trial has been conducted
with the use of tocilizumab in ESRD patients. Hence, the
manufacturer recommends against use in this population.
However, there are a few case reports that show efficacy of
tocilizumab in renally impaired patients. In November
2020, a case report involving tocilizumab for a 52-year-old
COVID-19 patient with ESRD on hemodialysis showed
rapid improvement and became afebrile 24 h after administration.11 In another case report, an Australian patient on
long-term hemodialysis with severe COVID-19 was treated
with tocilizumab on day 7 of her hospital stay. The case
report showed a significant and immediate decrease in her
inflammatory markers.12 Tocilizumab also has the approved
indication for rheumatoid arthritis, where it also has limited
data regarding safety with ESRD patients. In 2015, a study
that took place in Japan analyzed the effect between tocilizumab and methotrexate, another rheumatoid arthritis agent,
in patients with ESRD. Efficacy parameters in the renal
insufficiency group with tocilizumab were like those in the
methotrexate group. There were also no significant differences in rates of dropout, adverse events, or severe adverse
events between the two groups for patients with and without
renal insufficiency.13
Finally, corticosteroids have become the mainstay of
treatment for COVID-19. A cohort study published in May
2021 with 216 COVID-19 positive patients compared dexamethasone and methylprednisolone. The patients received
methylprednisolone 250–500 mg IVPB for 3 days followed
by prednisone 50 mg orally for 14 days or dexamethasone
6 mg orally for 7–10 days. The maximum amount of methylprednisolone given was 1 g IVPB for up to 7 days. Both
groups were shown to decrease recovery time and severity
markers, including CRP and ferritin.14 This use of corticosteroids was also studied in the RECOVERY trial that
included 2104 patients hospitalized with COVID-19. The
patients received either dexamethasone 6 mg orally or intravenous once daily for up to 10 days plus usual care or usual
care alone. The results showed that the dexamethasone group
had a lower 28-day mortality rate in patients who received
invasive mechanical ventilation or oxygen therapy alone.14,15
Due to the current available published data, our patient was
given methylprednisolone 1 g IVPB for 3 days followed by
methylprednisolone 40 mg twice a day, remdesivir for 5 days,
and one dose of tocilizumab 8 mg/kg.
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We believe that this is the first reported case of COVID19 pneumonia in an ESRD patient who was treated with the
combination of pulse dose methylprednisolone, tocilizumab,
and remdesivir. Our case report shows that a single dose of
tocilizumab (8 mg/kg), along with remdesivir and methylprednisolone, reduces the symptoms and decreases inflammatory biomarkers in a patient who tested positive for
COVID-19 with ESRD. While there is a plethora of data for
the use of the three agents (steroids, remdesivir, and tocilizumab) in non-ESRD patients, there has not been published
guidelines regarding their use in ESRD COVID-19 patients.
In addition, our case report included the use of the pulsedose methylprednisolone (a dose larger than the currently
suggested by the RECOVERY trial). Hence, our study proposes the need to investigate the role of higher doses of steroid in combination with remdesivir, and tocilizumab in this
patient population.

Conclusion
In light of COVID-19 delta variant and growing population
of ESRD patients, a triple therapy consisting of pulse dose
methylprednisolone, tocilizumab, and remdesivir can be
considered as a treatment option. However, randomized controlled trials are warranted to assess its safety and efficacy of
the noted regimen.
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